Sodium–glucose co-transporter-2 inhibitors (SGLT2 inhibitors) have emerged as important therapeutic agents in the treatment of various metabolic diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD), type 2 diabetes mellitus (T2DM), and cardiovascular-related disorders [129]. Here, SLC5A2 is linked to type 2 diabetes mellitus.